Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Altimmune, Inc. (NASDAQ:ALT) has been given a consensus recommendation of “Moderate Buy” by the ten analysts that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $18.00.

Several research firms have issued reports on ALT. B. Riley Financial dropped their target price on Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Wall Street Zen cut Altimmune from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. William Blair reiterated a “market perform” rating on shares of Altimmune in a research note on Thursday, March 5th. HC Wainwright increased their price objective on Altimmune from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research note on Friday, March 27th.

Insider Activity

In other news, CEO Jerome Benedict Durso acquired 20,000 shares of the business’s stock in a transaction dated Friday, March 6th. The stock was bought at an average cost of $3.54 per share, for a total transaction of $70,800.00. Following the completion of the transaction, the chief executive officer owned 32,500 shares of the company’s stock, valued at $115,050. The trade was a 160.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have bought 30,000 shares of company stock valued at $108,900 over the last quarter. Corporate insiders own 1.60% of the company’s stock.

Institutional Trading of Altimmune

A number of hedge funds and other institutional investors have recently bought and sold shares of ALT. Hsbc Holdings PLC boosted its holdings in Altimmune by 80.8% in the 4th quarter. Hsbc Holdings PLC now owns 132,221 shares of the company’s stock valued at $474,000 after purchasing an additional 59,095 shares during the period. Rockefeller Capital Management L.P. increased its holdings in shares of Altimmune by 79,838.9% in the fourth quarter. Rockefeller Capital Management L.P. now owns 43,167 shares of the company’s stock worth $156,000 after purchasing an additional 43,113 shares during the period. Virtu Financial LLC raised its position in shares of Altimmune by 21.7% in the fourth quarter. Virtu Financial LLC now owns 58,477 shares of the company’s stock worth $211,000 after buying an additional 10,409 shares in the last quarter. Invesco Ltd. raised its position in shares of Altimmune by 32.7% in the fourth quarter. Invesco Ltd. now owns 214,824 shares of the company’s stock worth $776,000 after buying an additional 52,881 shares in the last quarter. Finally, Vines Capital Management LLC bought a new stake in Altimmune during the fourth quarter valued at $65,000. Institutional investors own 78.05% of the company’s stock.

Altimmune Stock Performance

NASDAQ ALT opened at $3.12 on Thursday. The company has a market capitalization of $405.91 million, a PE ratio of -3.09 and a beta of 0.34. The company has a debt-to-equity ratio of 0.15, a quick ratio of 18.55 and a current ratio of 18.55. Altimmune has a 52-week low of $2.87 and a 52-week high of $7.73. The company has a 50-day simple moving average of $4.26 and a 200 day simple moving average of $4.25.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 49.35%. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.00 million. On average, research analysts predict that Altimmune will post -1.35 EPS for the current year.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.